sur CROSSJECT (EPA:ALCJ)
Maxim Group Recommends CROSSJECT with €4.00 Target Price
Maxim Group, a US brokerage focused on biopharmaceuticals, has initiated coverage of CROSSJECT, a specialty pharma company. They have issued a BUY recommendation for CROSSJECT's shares, setting a target price of €4.00. As of May 29, 2025, the shares were priced at €1.77.
CROSSJECT, headquartered in Dijon, France, specializes in needle-free auto-injector platforms for emergency therapies. Their flagship product, ZEPIZURE®, is in advanced phases of development and registration. The company has a significant contract with BARDA for this epileptic rescue therapy.
Patrick Alexandre, CEO of CROSSJECT, expressed enthusiasm for Maxim's endorsement, emphasizing their commitment to advancing developments, especially in North America.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de CROSSJECT